COVID-19 Activities

COVID-19 Activities of EU-OPENSCREEN Partner Sites

CZ (Czech Republic)

Institute of Molecular Genetics (IMG)

Screening Site

CZ-OPENSCREEN

 

COVID-19 ActivityStatus
Real-time monitor for scientific data and publications in the area of High-throughput screening for SARS-CoV-2 presence in population, Coronatest Hackathon
P. Bartůněk, S. Simova
Ongoing

Petr Bartůněk

bartunek@img.cas.cz

DE (Germany)

Helmholtz-Zentrum für Infektionsforschung (HZI)

Activity Profile

The HZI offers a fully automated system for screening campaigns under BSL2-conditions, which is suitable for either target-based assays or phenotypic assays using the coronavirus H229E. In addition the activity of identified hits from target-based screens against the whole virus SARS-Cov-2 can be validated in the BSL3 laboratory. This laboratory is also fully equipped for screening campaigns, in a smaller scale, using a semi-automated system. Moreover, support can be offered for chemical optimisation of compounds and for evaluation of preclinical parameters, such as ADME-Tox and PK/PD properties.

Screening Site

Department of Chemical Biology (CBIO)

 

 

COVID-19 ActivityStatus
H2020-MSCA-ITN-2020: "TRAINAT" (antivirals from natural products)
M. Brönstrup
Submitted
EU-project 'SCORE': Contribution to optimization of protease inhibitors
K. Rox, M. Brönstrup
Accepted
Screening in house libraries for anti-SARS-CoV2-inhibitors in target-based and phenotypic viral assays
U. Bilitewski, M. Brönstrup
Ongoing

Mark Brönstrup / Ursula Bilitewski / Katharina Rox

Mark.Broenstrup@helmholtz-hzi.de

Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)

Screening Site

Department ScreeningPort

 

COVID-19 ActivityStatus
Horizon 2020 Excalate4CoV, Computer-Aided Drug Design (CADD) in combination with High-Throughput Screening (biochemical and phenotypic)
B. Ellinger, A. Zaliani, P. Gribbon
Accepted
Screening of the Fraunhofer Repurposing Set (BROAD Library; approx. 5.600 compounds) in a cell-based viral replication assay
B. Ellinger, P. Gribbon
Accepted
Real-time search-engine for scientific data and publications in the area of SARS-CoV-2/COVID19 (text and data mining) for the identification of potential targets for Drug Discovery (e.g. for drug repurposing) 
B. Ellinger, P. Gribbon
Accepted
Development and implementation of a a self-test kit for COVID-19 and an algorithm for data analysis H2020 Enhanced EIC Accelerator Pilot (SME Instrument Phase 2)
S. Gul, P. Gribbon
Submitted
IMI call: Therapeutics against pan-coronaviruses (NOCORON)
S. Gul, P. Gribbon
Submitted
Several BMBF applications in the frame of a COVID-19 rapid response call (Förderaufruf zur Erforschung von COVID-19 im Zuge des Ausbruchs von Sars-CoV-2) focusing on the use of the Fraunhofer Repurposing Set (BROAD Library; approx. 5.600 compounds) in the fields of systems biology, lung models and animal models.
B. Ellinger, O. Pless, M. Grättinger, P. Gribbon
Ongoing

Bernhard Ellinger, Mira Grättinger, Phil Gribbon, Sheraz Gul, Ole Pless, Andrea Zaliani

Bernhard.Ellinger@ime.fraunhofer.de

ES (Spain)

Fundación MEDINA (MEDI)

Screening Site

Screening and target validation, Microbiology and Chemistry

 

COVID-19 ActivityStatus
Developing in vitro screening approaches focused on viral and host targets
O. Genilloud
Ongoing
Planning antiviral discovery programs on target-based assays with MEDINA natural products libraries and external libraries
O. Genilloud
Planned
Looking for partners with BSL3 virus inhibition assays and infection animal models to test the antiviral activity of MEDINA malaria hits (Spanish Tropical Diseases network), and natural product analogs of drugs recently reported active on SARS-CoV-2 targets; Collaborating in other antiviral programs with the Univ. of Granada (Spain) and CICY (Mexico)
O. Genilloud
Ongoing
Identifying predictive and prognostic metabolomic biomarkers associated to the infection evolution from inactivated samples from COVID-19 patients at different infection stages.
O. Genilloud
Planned

Olga Genilloud

olga.genilloud@medinaandalucia.es

Prince Felipe Research Center (CIPF)

Screening Site

Screening Platform, Advanced Therapies Program

 

COVID-19 ActivityStatus
Restore the balance of the host immune response against Covid-19. Evaluation of new strategies for the restoration of body homeostasis in patients
M. J. Vicent
Planned

Maria Jesus Vicent

mjvicent@cipf.es

University of Santiago de Compostela (USC)

Screening Site

BioFarma Research Group

 

COVID-19 ActivityStatus
Repositioning against virus key targets and protein production of vaccines in different national proposals
M. Loza
Planned

Mabel Loza

mabel.loza@usc.es

FI (Finland)

Institute for Molecular Medicine Finland (FIMM)

Activity Profile

1. High throughput chemical and siRNA screening
2. Laboratory automation and access to HTS instrumentation: https://www.helsinki.fi/en/infrastructures/drug-discovery-chemical-biology-and-screening/infrastructures/high-throughput-biomedicine/instruments
3. Assay-ready plates and compound aliquots from our compound libraries: www.helsinki.fi/en/infrastructures/drug-discovery-chemical-biology-and-screening/infrastructures/high-throughput-biomedicine/chemical-compound-libraries.

Screening Site

High Throughput Biomedicine (HTB) unit

 

COVID-19 ActivityStatus
Drug repurposing for COVID-19 with an open high throughput drug screening platform in collaboration with Department of Virology, Department of Bacteriology and Immunology, Faculty of Medicine, and Helsinki University Hospital-HUS


P. Tammela, J. Saarela

Active

Päivi Tammela, Jani Saarela

paivi.tammela@helsinki.fi

LV (Latvia)

Latvian Institute of Organic Synthesis (OSI)

Medicinal Chemistry Site

Organic Synthesis Methodology Group

 

COVID-19 ActivityStatus

Drug re-purposing including the use of the drugs to facilitate the treatment of COVID complications
A. Jirgensons, O. Pugovics

Planned
Planning the development of manufacturing technologies for perspective generics (small molecules)
A. Jirgensons, O. Pugovics
Planned

Planning discovery programs for improving future antiviral drug arsenal We are open to collaboration with our drug discovery/ technology development expertise. Particularly, we are seeking for partners with capabilities and expertise in antiviral infection models
A. Jirgensons, O. Pugovics

Planned

Aigars Jirgensons, Osvalds Pugovics

aigars@osi.lv

PL (Poland)

Polish Academy of Sciences (IMB PAS)

Activity Profile

IMB PAS supported the organization and functioning of a new COVID-19 diagnostic laboratory at the Clinical and Didactic Center of the Medical University of Lodz together with the Medical University of Lodz, the Faculty of Biology and Environmental Protection of the University of Lodz, the company Proteon Pharmaceuticals S.A.
The laboratory started operating on March 23, 2020, prof. dr hab. n. med. Maciej Borowiec from the Medical University of Lodz was appointed as its head. Currently, IBM PAN together with Proteon Pharmaceuticals is creating a satellite Screening Center towards SARS-CoV-2 focused on fast, screening detection of people who are carriers of the virus.
Thanks to the support of the Ministry of Science and Higher Education, as part of the POL-OPENSCREEN project, the National Chemical Compounds Library (NCCL) is created at IBM PAN, the resources of NCCL will be available for screening in search for new bioactive compounds, including antiviral compounds. Screening of the library of compounds synthesized in IBM PAN, analogues of remdesivir as well as other molecules for anti-coronavirus activity have already been initiated.

Screening Site

Screening laboratory for anti-viral and anti-bacterial compounds

 

COVID-19 ActivityStatus

Collaborative testing of a library of remdesivir mimics synthesized in IMB PAS
Z. Lesnikowski

Ongoing

Zbigniew Lesnikowski

zlesnikowski@cbm.pan.pl

Institute of Bioorganic Chemistry Polish Academy of Sciences (IBCH PAS)

Activity Profile

IBCH PAS hosts a high-throughput screening platform, with automated liquid handling and multimodal detection. This allows for, both, the search for new therapies and preparations based on drugs used already for other diseases (so-called drug re-purposing) and discovery of new biologically active molecules. Screening is conducted on non-infectious virus models, human cells, proteins and nucleic acids.
The pilot EU-OPENSCREEN library of 2,500 bioactive compounds is also available to potential users at ICHB. Our efforts are also directed at the development of new and adaptation of existing molecular tests for high-throughput detection of binding of small molecules to biological models and their inhibition. As part of a broader initiative, IBCH PAS also offers support in discussions between business and academic partners interested in projects involving SARS-CoV-2.
In addition to establishing SARS-CoV-2 diagnostic laboratory (daily throughput of few hundred assays), a first Polish test have been developed at IBCH PAS and approved for use in Poland as alternative to commercial ones.

Screening Site

Centre for High-Throughput Screening Studies, Department of Molecular and Systems Biology, Department of RNA Structural Genomics, Department of Crystallography

 

COVID-19 ActivityStatus

Screening: developing and adapting assays for screening of binders / inhibitors of viral proteins / RNA / virus-host interactions

J. Kolanowski, R. Pilarski, M. Otrocka

Ongoing/

Applied

Performing tests for COVID-19 (supporting Polish healthcare system by aiding medical diagnostic labs with infrastructure and expertise), re-constituting classic PCR diagnostic test from our own resources (already successful - awaits approval to official use in testing)
M. Figlerowicz, L. Handschuh
Ongoing
Searching for new, faster, diagnostic tests (e.g. by fluorescence)
J. Kolanowski
Applied

Jacek Kolanowski

jacek.kolanowski@ibch.poznan.pl

Polish Academy of Sciences, Institute of Biochemistry and Biophysics (IBB PAS)

Activity Profile

IBB PAS, as part of joint operations of several located in Warsaw establishements, joined the organization and operation of the new CoVID-19 diagnostic laboratory. The diagnostic laboratory is headed by prof. Urszula Demkow from the University Clinical Center of the Warsaw Medical University. The Institute also donated the necessary laboratory equipment to the emerging laboratory.
Prof. Tomasz Sarnowski, in cooperation with the National Institute of Oncology and the Medical University of Warsaw, has started the implementation of the M13VHH CoV2 project financed by the Medical Research Agency aimed at developing anti-COVID-19 therapy based on phage therapy and the use of nanoproteins. In the Bioinformatics Department of IBB PAS headed by prof. Piotr Zielenkiewicz the virtual screening campaigns was initiated focused on:
1. virtual search for protein ligands;
2. search for peptide protein-protein interaction inhibitors; and
3. Identification and attempt to experimentally verify the use of plant miRNAs that may affect the multiplication and assembly of CoVID019.

Contact persons:
Prof. dr hab. Zbigniew Leśnikowski (IMB PAS): zlesnikowski@cbm.pan.pl;
Dr Jacek Kolanowski (IBCH PAS): jacek.kolanowski@ibch.poznan.pl (for COVID-19 diagnostic tests please contact dr Luiza Handschuh: luiza.handschuh@ibch.poznan.pl);
Prof. dr hab. Piotr Zielenkiewicz (IBB PAS): piotr@Ibb.waw.pl

Medicinal Chemistry Site

Department of Bioinformatics

 

COVID-19 ActivityStatus

Design of spkie protein-Ace2 interaction inhibitors; Design of miRNAs to prevent virus entry/multiplication
P. Zielenkiewicz

Ongoing, Proposals

Piotr Zielenkiewicz

piotr@ibb.waw.pl